Kyoto, Japan (ots/PRNewswire) - - Further Therapeutic Potential of Pramipexole to be Investigated in New Disease-Modification Trial - For non-US Healthcare Media New data presented today from a meta-analysis* of nearly 1,300 Parkinson's disease (PD) patients indicate that pramipexole (Mirapexin(R) ...
Shire Pharmaceuticals Group Plc
Basingstoke, England (ots/PRNewswire) - Shire today announced the start of a new Phase IIIb clinical trial to evaluate two new dosing schedules of DYNEPO(R) (epoetin delta), the first commercial erythropoiesis-stimulating agent produced in a human cell line. DYNEPO is used in the treatment of anaemia in patients with chronic kidney disease (CKD[i]). Anaemia becomes ...
New York (ots/PRNewswire) - - Madrid, Spain Court of Appeal Confirms Pfizer's Patent Claims Pfizer Inc said today that the European Patent Office (EPO) has issued an opinion upholding, in its entirety, the company's calcium salt patent covering Lipitor. The opinion was provided at the request of a Spanish court that is hearing a patent infringement case filed against Pfizer by generic manufacturer Ranbaxy. ...
Madrid, Spain (ots/PRNewswire) - - Zeltia Revenues up 10% and R&D Expenditure Rises 19% - Net Revenues Amounted To 64.3 Million Euro - Research and Development Expenditure Amounted to 36.8 Million Euro Zeltia S.A. (ZEL SM; ZEL MC) reported 64.3 million euro in net revenues in the first nine months of 2006, a 10% increase on the same period of 2005 (58.3 million euro). Research and development expenditure increased by 19% year-on-year to 36.8 million ...
Brussels, Belgium (ots/PRNewswire) - Preliminary results from the world's most comprehensive global stroke survey are announced today by the Stroke Alliance for Europe (SAFE) and AstraZeneca (NYSE:AZN). The initial survey results point to a widespread lack of awareness of stroke. Eighty one per cent of patients and carers surveyed were not aware of stroke's ...
New York (ots/PRNewswire) - - Company Opens its Compound Library to Help Search for New Anti-Parasitic Medicines Pfizer announced today collaboration that gives access to its library of medicinal compounds -- the world's largest -- and also brings scientists from developing countries into ...
Tolochenaz, Switzerland (ots/PRNewswire) - A new study announced today by Medtronic will investigate the short and long-term benefits of adding a spinal stabilisation system to a standard herniectomy procedure in patients with spinal disc herniation. The study is the first randomised control trial to assess the ...
Berlin, Germany (ots/PRNewswire) - - Global Survey Highlights Misunderstandings About Causes and Treatment of Constipation - Not for use or publication in the USA Many people with constipation are confused about the cause of their condition and its appropriate treatment with laxatives. Results of a new large-scale global survey, announced today, show ...
Paris (ots/PRNewswire) - GenOdyssee S.A., a biotechnology company dedicated to the discovery of novel protein therapeutic products, has entered into a research and development cooperation agreement with Baxter AG. GenOdyssee will use its unique intellectual property position in the field of protein therapeutics, as well as its proprietary technology and integrated processes, in the discovery of novel blood clotting ...
Boston, Massachusetts and Paris (ots/PRNewswire) - KIKA Medical, a provider of advanced web-based solutions for Clinical Studies, announced the appointment of Shubh L. Sethi as Chief Operating Officer (COO). "Shubh brings unique credentials to the company at a time KIKA Medical is poised for growth on both sides of the Atlantic" said Gerard Moufflet, CEO, KIKA Medical "He has extensive experience in various markets ...
Boston, Massachusetts and Paris (ots/PRNewswire) - - KIKA Medical Will Provide Global EDC Services for One of the Largest Drug-Eluting Stent Registries in the Cardiovascular Field KIKA Medical, a provider of advanced web-based solutions for Clinical Studies, announces today that it has been selected to provide EDC services for one of the largest drug-eluting stent post-marketing registries in the ...
Vienna, Austria (ots/PRNewswire) - sanofi pasteur, [NYSE: SNY] the vaccines business of the sanofi-aventis Group, today announced that its H5N1 pre-pandemic vaccine induces antibodies that neutralize additional H5N1 circulating virus not included in the original vaccine formulation. These data, presented at the 2nd International Conference on Influenza Vaccines ...
Fukuoka, Japan (ots/PRNewswire) - - Therapy May Benefit Hypertensive Patients With Additional Risk Factors in Populations Across Asia and Latin America Single-pill amlodipine besylate/atorvastatin calcium (Caduet(R)) may reduce the 10-year risk of having a cardiovascular (CV) event - as determined by the ...
New York (ots/PRNewswire) - Pfizer said today that the Austrian Patent Office has ruled that a claim in the company's basic patent covering the use of atorvastatin, the active ingredient in Lipitor, would be infringed by generic manufacturer Ranbaxy. Ranbaxy can appeal the ruling, but the patent will remain ...
Bristol-Myers Squibb Medical Imaging
N. Billerica, Massachusetts (ots/PRNewswire) - Bristol-Myers Squibb Medical Imaging announced today that the European Commission has granted marketing authorisation for LUMINITY(TM), an ultrasound contrast agent, for use in patients with suboptimal echocardiograms who have suspected or established ...
Basel, Switzerland (ots/PRNewswire) - - FDA Grants Fast Track Status to R1626 Roche announced today the start of the first phase II development study to evaluate R1626, their promising new polymerase inhibitor, for the treatment of hepatitis C. The investigational drug has also been granted Fast Track ...
Fachhochschule Graubünden / FH Graubünden
Chur (ots) - St. Moritz, Davos, Arosa - three resounding Swiss tourism destinations. All three towns lie in the canton of Grisons (Graubünden), the capital of which is Chur, home to the University of Applied Sciences Chur HTW Chur, founded in 1963. Approximately 1,400 students may choose from five Swiss federally approved and internationally recognized Bachelor ...
Bristol-Myers Squibb Medical Imaging
Journalists and other readers should disregard the news release "Bristol-Myers Squibb Medical Imaging Receives European Commission Marketing Authorisation for Its Ultrasound Contrast Agent LUMINITY(TM) (perflutren lipid microsphere)" NYSE:BMY, issued earlier today. The release was issued prematurely by PR Newswire. ots Originaltext: Bristol-Myers Squibb Medical ...
Bristol-Myers Squibb Medical Imaging
N. Billerica, Massachusetts (ots/PRNewswire) - Bristol-Myers Squibb Medical Imaging announced today that the European Commission has granted marketing authorisation for LUMINITY(TM), an ultrasound contrast agent, for use in patients with suboptimal echocardiograms who have suspected or established ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) reports final safety and efficacy data subsequent to 60 weeks of continuous treatment with ISA247. All safety and efficacy endpoints were met. Patients completing the 24 week Canadian Phase III SPIRIT trial were given the opportunity to continue ISA247 therapy at a 0.3 mg/kg twice daily oral dose ...
New York (ots/PRNewswire) - - Prototype Research Kits Approach Commercialization Phase and Target the Growing Field of Genomic-Based Molecular Diagnostics Xenomics, Inc. (OTC Bulletin Board: XNOM; FWB:XE7), the source of next-generation medical DNA diagnostic tests, today announced that it has developed a new method for the isolation of low molecular ...
Basel (ots/PRNewswire) - - Results Unveiled at ICAAC Show That Over 90% of Treatment-Experienced Patients Achieve Treatment Goal of Undetectable Viral Load Exciting new clinical data demonstrate that 90 to 95 percent of treatment-experienced HIV patients who initiate therapy with FUZEON(R) (enfuvirtide) ...
Madrid (ots/PRNewswire) - PharmaMar today announced the successful planned review by the Independent Data Monitoring Committee (IDMC) of the YONDELIS(R) (trabectedin) Phase III pivotal clinical trial in ovarian cancer, known as OVA-301. The IDMC recommended that the present study should continue without ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company received a No Objection Letter from Health Canada to conduct a pivotal Phase III European /Canadian clinical trial for the treatment of moderate to severe psoriasis with its lead immunosuppressive drug, ISA247. The Company ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has been issued European Patent No. EP0991660 for its lead immunosuppressive drug, ISA247. The patent entitled "DEUTERATED AND UNDEUTERATED CYCLOSPORINE ANALOGS AND THEIR USE AS IMMUNOMODULATING AGENTS" is the ninth patent to be issued internationally in this patent family. ...
Macclesfield, England (ots/PRNewswire) - - For International Journalists - Not for US Media New data, presented for the first time today, show that a combination of ARIMIDEX(TM)(anastrozole) plus Herceptin (trastuzumab) is a better treatment option than hormonal therapy alone, for women with a certain ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company received approval from the German Competent Authority to conduct a pivotal Phase III clinical trial for the treatment of moderate to severe psoriasis with its lead immunosuppressive drug, ISA247. The Phase III ...
NEW- YORK, September 29 (ots/PRNewswire) - Sanofi Pasteur, the vaccines business of sanofi-aventis, and the Pediatric Dengue Vaccine Initiative (PDVI) announced today their partnership to help develop and make a Dengue vaccine widely available for the global prevention of Dengue fever, the second most widespread tropical disease after malaria. Dengue fever ...
Istanbul, Turkey (ots/PRNewswire) - PharmaMar, the biopharmaceutical company specialising in cancer therapy, announces today that it is to present new data from two of its clinical compounds, Kahalalide F and Aplidin(R), at the 31st European Society for Medical Oncology Congress (ESMO) being held in Istanbul, Turkey from 29 September to 3 October 2006. Data will ...
Alderley Park, England (ots/PRNewswire) - - First Patient Enrolled in Pivotal International Randomised, Double-Blind Study of Vandetanib Versus Erlotinib FOR NON-US HEALTHCARE PROFESSIONAL PRESS ONLY AstraZeneca (NYSE:AZN) today announced the start of enrolment into a new Phase III study of the novel ...